The myostatin gene: physiology and pharmacological relevance

Current Opinion in Pharmacology

Volumn 7, Issue 3, 2007, Pages 310-315

  Joulia Ekaza, Dominique ^a   Cabello, Gérard ^b  

^a UNIVERSITÉ NANGUI ABROGOUA   (Côte d’Ivoire)

^b University of Montpellier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; CANCER GROWTH FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEXAMETHASONE; FORKHEAD TRANSCRIPTION FACTOR; GLUCOCORTICOID; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MYOSTATIN; MYOSTATIN RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

CATTLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; DEGENERATIVE DISEASE; DRUG TARGETING; GENE DISRUPTION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HYPERPLASIA; MOLECULAR CLONING; MOLECULAR MECHANICS; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; SATELLITE CELL; SKELETAL MUSCLE; WEIGHT REDUCTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MUSCULAR ATROPHY; TRANSFORMING GROWTH FACTOR BETA;

EID: 34248324912     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.11.011     Document Type: Review

References (46)

1. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997) 83-90
2. Gonzalez-Cadavid N.F., Taylor W.E., Yarasheski K., Sinha-Hikim I., Ma K., Ezzat S., Shen R., Lalani R., Asa S., Mamita M., et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 95 (1998) 14938-14943
3. Ostbye T.K., Galloway T.F., Nielsen C., Gabestad I., Bardal T., and Andersen O. The two myostatin genes of Atlantic salmon (Salmo salar) are expressed in a variety of tissues. Eur J Biochem 268 (2001) 5249-5257
4. Ji S., Losinski R.L., Cornelius S.G., Franck G.R., Willis G.M., Gerrard D.E., Depreux F.F.S., and Spurlock M.E. Myostatin expression in porcine tissues: tissue specificity and developmental and postnatal regulation. Am J Physiol 275 (1998) R1265-R1273
5. Rodgers B.D., Weber G.M., Sullivan C.V., and Levine M.A. Isolation and characterization of myostatin complementary deoxyribonucleic acid clones from two commercially important fish: Oreochromis mossambicus and Morone chrysops. Endocrinology 142 (2001) 1412-1418
6. Maccatrozzo L., Bargelloni L., Radaelli G., Mascarello F., and Patarnello T. Characterization of the myostatin gene in the gilthead seabream (Sparus aurata): sequence, genomic structure, and expression pattern. Mar Biotechnol (NY) 3 (2001) 224-230
7. Smith T.P., Lopez-Corrales N.L., Kappes S.M., and Sonstegard T.S. Myostatin maps to the interval containing the bovine mh locus. Mamm Genome 8 (1997) 742-744
8. Joulia-Ekaza D., and Cabello G. Myostatin regulation of muscle development: Molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 312 (2006) 2401-2414
9. Schuelke M., Wagner K.R., Stolz L.E., Hübner C., Riebel T., Kömen W., Braun T., Tobin J.F., and Lee S.J. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350 (2004) 2682-2688
10. Spiller M.P., Kambadur R., Jeanplong F., Thomas M., Martyn J.K., Bass J.J., and Sharma M. The myostatin gene is a downstream target gene of basic helix-loop-helix transcription factor MyoD. Mol Cell Biol 22 (2002) 7066-7082
11. Ma K., Mallidis C., Bhasin S., Mahabadi V., Artaza J., Gonzalez-Cadavid N., Arias J., and Salehian B. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285 (2003) 363-371
12. Gilson H., Shackman O., Combaret L., Lause P., Grobet L., Attaix D., Ketelslegers J.M., and Thissen J.P. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148 (2007) 452-460
13. Allen D.L., and Unterman T.G. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 292 (2007) C188-C199. This paper indicates that FoxO1 is involved in positive regulation of myostatin expression, thus suggesting that induction of muscle atrophy by this transcription factor could inhibit muscle regeneration through the myostatin pathway, in addition to proteolysis induction.
14. Lee S.J., and McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98 (2001) 9306-9311
15. Zhu X.Y., Topouzis S., Liang L.F., and Stotish R.L. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine 26 (2004) 262-272
16. Thomas M., Langley B., Berry C., Sharma M., Kirk S., Bass J., and Kambadur R. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275 (2000) 40235-40243
17. Rios R., Carneiro I., Arce V.M., and Devesa J. Myostatin regulates cell survival during C2C12 myogenesis. Biochem Biophys Res Commun 280 (2001) 561-566
18. Rios R., Carneiro I., Arce V.M., and Devesa J. Myostatin is an inhibitor of myogenic differentiation. Am J Physiol Cell Physiol 282 (2002) C993-C999
19. Joulia D., Bernardi H., Garandel V., Rabenoelina F., Vernus B., and Cabello G. Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res 286 (2003) 263-275
20. ••], it appears that a positive regulatory loop occurs between FoxO1 and myostatin pathways, thus potentiating muscle wasting.
21. Carlson C.J., Booth F.W., and Gordon S.E. Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol 277 (1999) R601-R606
22. Dasarathy S., Dodig M., Muc S.M., Kalhan S.C., and McCullough A.J. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol 287 (2004) G1124-G1130
23. Kawada S., Tachi C., and Ishii N. Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. J Muscle Res Cell Motil 22 (2001) 627-633
24. Welle S., Bhatt K., Shah B., and Thornton C. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62-77 and 21-31 yr old men. Exp Gerontol 37 (2002) 833-839
25. Baumann A.P., Ibebunjo C., Grasser W.A., and Paralkar V.M. Myostatin expression in age and denervation-induced skeletal muscle atrophy. J Musculoskelet Neuronal Interact 3 (2003) 8-16
26. Wehling M., Cai B., and Tidball J.G. Modulation of myostatin expression during modified muscle use. FASEB J 14 (2000) 103-110
27. McCroskery S., Thomas M., Maxwell L., Sharma M., and Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162 (2003) 1135-1147
28. Zhu X., Hadhazy M., Wehling M., Tidball J.G., and McNally E.M. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474 (2000) 71-75
29. Yang J., Ratovitski T., Brady J.P., Solomon M.B., Wells K.D., and Wall R.J. Expression of myostatin pro domain results in muscular transgenic mice. Mol Reprod Dev 60 (2001) 351-361
30. Whittemore L.A., Song K., Li X., Aghajanian J., Davies M., Girgenrath S., Hill J.J., Jalenak M., Kelley P., Knight A., et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300 (2003) 965-971
31. Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A.F., Tomkinson K.N., McPherron A.C., Wolfman N.M., and Lee S.J. Induction of cachexia in mice by systemically administered myostatin. Science 296 (2002) 1486-1488
32. Wagner K.R., Liu X., Chang X., and Allen R.E. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA 102 (2005) 2519-2524
33. McCroskery S., Thomas M., Platt L., Hennebry A., Nishimura T., McLeay L., Sharma M., and Kambadur R. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118 (2005) 3531-3541
34. Bogdanovich S., Krag T.O.B., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., and Khurana T.S. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
35. Wagner K.R., McPherron A.C., Winik N., and Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52 (2002) 832-836
36. Bogdanovich S., Perkins K.J., Krag T.O.B., Whittemore L.A., and Khurana T.S. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19 (2005) 543-549. Using myostatin propeptide injections to block the myostatin pathway, the authors describe the benefits for mdx mice, especially with regard to muscle strength.
37. Benabdallah B.F., Bouchentouf M., and Tremblay J.P. Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal. Transplantation 79 (2005) 1696-1702. Transplantation into mdx mice of myoblasts expressing dnActRIIB, a dominant-negative mutant of the myostatin type II receptor, leads to more abundant and larger dystrophin-positive fibres.
38. Parsons S.A., Millay D.P., Sargent M.A., McNally E.M., and Molkentin J.D. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 168 (2006) 1975-1985
39. Ohsawa Y., Hagiwara H., Nakatani M., Yasue A., Moriyama K., Murakami T., Tsuchida K., Noji S., and Sunada Y. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 116 (2006) 2924-2934
40. Li Z.F., Shelton G.D., and Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 166 (2005) 491-497
41. Thies R.S., Chen T., Davies M.V., Tomkinson K.N., Carson A.A., Shakey Q.A., and Wolfman N.M. GDF8 propeptide binds to GDF8 and antagonizes biological activity by inhibiting GDF8 receptor binding. Growth Factors 18 (2001) 251-259
42. Hill J.J., Qiu Y., Hewick R.M., and Wolfman N.M. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 17 (2003) 1144-1154
43. Hill J.J., Davies M.V., Pearson A.A., Wang J.H., Hewick R.M., Wolfman N.M., and Qiu Y.C. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277 (2002) 40735-40741
44. Wang H., Zhang Q., and Zhu D. hSGT interacts with the N-terminal region of myostatin. Biochem Biophys Res Commun 311 (2003) 877-883
45. Nicholas G., Thomas M., Langley B., Somers W., Patel K., Kemp C.F., Sharma M., and Kambadur R. Titin-cap associates with, and regulates secretion of, myostatin. J Cell Physiol 193 (2002) 120-131
46. Amthor H., Nicholas G., McKinnell I., Kemp C.F., Sharma M., Kambadur R., and Patel K. Follistatin complexes Myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270 (2004) 19-30